AIMNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

AIM ImmunoTech Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026

$0.16−0.01 (-2.97%)

Close on Oct 19, 2026

Market cap: $2.79M
P/E (TTM): –
Dividend yield: –

AIM ImmunoTech Inc. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31
Revenue	0.09	0.17	0.20	0.14	0.14	0.16	0.14	0.37	0.44	0.09	0.13	0.20	0.15	0.21	0.16	0.14	0.11
Cost of Revenue	–	–	–	–	–	–	–	–	–	–	–	1.25	1.23	1.99	1.04	1.34	0.58
Gross Profit	–	–	–	–	–	–	–	–	–	–	–	-1.05	-1.08	-1.78	-0.88	-1.21	-0.47
Research & Development	3.92	6.20	11	6.99	7.67	5.72	4.65	4.78	4.10	5.11	8.04	8.99	8.36	9.51	6.72	7.61	7.00
General & Administrative	7.70	14	21	13	8.67	8.65	7.04	6.20	6.57	7.68	7.15	9.06	7.72	9.06	6.69	7.57	5.80
Total Costs & Expenses	12	20	32	20	19	15	13	12	12	14	17	19	17	21	14	17	13
Operating Income	-12	-20	-32	-20	-19	-15	-12	-11	-11	-14	-17	-19	-17	-20	-14	-16	-13
Interest Expense	0.81	0.59	–	–	0.07	0.67	0.43	0.20	–	–	0.00	0.01	0.02	0.02	0.04	0.01	0
Other Non-Operating Income	3.18	5.19	1.07	0.63	–	–	–	–	–	–	–	–	0.78	1.57	0.58	2.37	–
Asset Impairment Charges	–	–	–	–	1.80	0.14	–	–	–	–	–	–	–	–	–	–	–
Gain (Loss) on Investments	0.02	-0.09	0.20	-1.68	-0.20	0.22	–	0.01	0.02	-0.06	-0.06	0.05	–	–	–	–	–
Gain (Loss) on Sale of Assets	–	–	0.02	0.00	0.22	–	–	0.22	–	–	–	–	–	–	0	0	0.08
Legal Settlements	–	–	–	–	–	–	-1.22	0.47	–	–	–	–	–	–	–	–	–
Pretax Income	-14	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Net Income incl. Noncontrolling Interests	–	–	–	–	–	–	–	–	–	–	–	-17	-16	-17	-9.02	-13	-7.18
Net Income	-14	-17	-29	-19	-19	-14	-9.40	-9.83	-8.26	-7.50	-15	-17	-16	–	–	–	–
EPS (Basic)(per share)	-8.62	-30.92	-60.00	-40.00	-40.00	-45.00	-258.00	-977.00	-1,276.00	-1,496.00	-3,388.00	-4,884.00	-5,280.00	-6,336.00	-3,696.00	-5,280.00	-3,696.00
EPS (Diluted)(per share)	-8.62	-30.92	-60.00	-40.00	-40.00	-45.00	-258.00	-977.00	-1,276.00	-1,496.00	-3,388.00	-4,884.00	-5,280.00	-6,336.00	-3,696.00	-5,280.00	-3,696.00
Shares Outstanding (Basic, Weighted)(shares)	1.62	0.56	0.49	–	0.47	0.32	0.04	0.01	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	–
Shares Outstanding (Diluted, Weighted)(shares)	1.62	0.56	0.49	0.48	0.47	0.32	0.04	0.01	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -11724.2%
Net margin: -15021.1%
Return on equity, FY2025: 251.4%

Financial strength

Current ratio: 2.11
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 200.2%

Valuation

P/E ratio: –
Price to sales: 29.39
Price to book: 0.36
Dividend yield: –